luca-nicoletti-jKZ2iUsaqXk-unsplash_edited_edited.jpg
white geometrical spherelike-01.png
Oligomedic_PrimaryRev_StackedLogo no plus.png

Biomaterials for a better life

PLUS only.png

The last mile of delivering a drug to a patient occurs in their own body - from the circulatory system to the intended organ.

 

Oligo Medic has developed a versatile, polysaccharide-based proprietary nanoparticle architecture with the potential to improve the benefits and reduce the risks for a wide class of therapeutic molecules.

  Seeking the full
 
potential of biomaterials

Learn more

minimal_technoligs logo-04.png
PLUS only.png

We developed a proprietary nanoparticle architecture combining stealth and active targeting to efficiently deliver a wide range of therapeutic payloads, drastically increasing the proportion of drug reaching the intended target, even when the target escapes to unexpected tissues.

This type of targeting has limitless potential, from rare diseases to disease that suffer from off-target adverse events!

Confirmatory Phase

Target

Encapsulated Drug

Rights

Solid Tumors
Selected anticancer drugs
Fully owned
Preclinical Phase

We are ready to boost the development of stealthy targeting for its full market potential through collaborative efforts

minimal_technoligs logo-02.png
PLUS only.png

We are in talks with the FDA for a superior alternative to HA injections with fundamentally longer residence time, designed for effective and long-lasting lubrication of joints under abrasive stress.

minimal_technoligs logo-03.png
PLUS only.png

We designed an improved dermal injection for creating facial volume with the same satisfactory characteristics of HA, but fundamentally longer lasting outcomes.

R&D

Preclinical

Clinical

Commercial

JointRep®

JL-001

DR-001

Our medical device journey started with JointRep®, find out more!

jr white-01.png